In Q3 2024, Avoro Capital Advisors held 33 positions worth $6.7B. They exited 22. Their largest holding was UTHR ($1.0B). Portfolio value shrank -5.0% versus the prior quarter.
Frequently asked questions
What stocks did Avoro Capital Advisors own in Q3 2024?
Avoro Capital Advisors held 33 biotech stocks in their 13F portfolio in Q3 2024. Their top positions include UTHR, ASND, ARGX, KRYS, MDGL. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Avoro Capital Advisors's portfolio worth in Q3 2024?
Avoro Capital Advisors's tracked biotech portfolio was worth $6.7B across 33 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Avoro Capital Advisors buy in Q3 2024?
Avoro Capital Advisors did not initiate any new positions in Q3 2024, but increased 10 existing holdings.
What did Avoro Capital Advisors sell in Q3 2024?
Avoro Capital Advisors fully exited 22 positions in Q3 2024, including PMVP, SGEN, MCRB, TNGX, DSGN and 17 more. They also trimmed 8 existing positions.
Is Avoro Capital Advisors a biotech fund?
Biotech specialist fund (formerly Venbio Select Advisor) that takes concentrated positions in clinical and commercial-stage companies. Aghazadeh, a biochemist, is known for activist-style engagement and has served on multiple biotech boards to drive value creation.
Want AI analysis, insider signals, and catalyst overlays for Avoro Capital Advisors?
View latest Avoro Capital Advisorsportfolio →